Author

Hemant Kumar

Indian Institute of Technology BhubaneswarPrimary ORCID profile (0000-0002-6434-0245 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Hemant KumariD1 paper · National Institute of Pharmaceutical Education and Research - Ahmedabad

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Assay:Hi-C· 1

Frequent Co-Authors

Dimple NotaniiD· 1 shared Jyothi S. PrabhuiD· 1 shared Mohit Kumar JollyiD· 1 shared Sarthak SahooiD· 1 shared Sejal Khanna· 1 shared Sridhar S. HannenhalliiD· 1 shared Swayamshree SenapatiiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Dimple NotaniORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer

Sarthak Sahoo, Sejal Khanna, Swayamshree Senapati, Hemant Kumar, Jyothi S. Prabhu, Dimple Notani, Sridhar S. Hannenhalli, Mohit Kumar Jolly

This study identifies drug-specific resistance mechanisms in ER+ breast cancer by analyzing multi-omic data, revealing distinct transcriptional and chromatin states associated with SERM, SERD, and ESR1 mutant resistance.

bioRxiv · May 13, 2026 · PreprintCancer Biology